Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations are empty, so the description bears full responsibility for behavioral disclosure. It only states it searches studies, with no mention of rate limits, data freshness, authentication needs, or that it is read-only. The behavioral traits are largely implicit.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is a single, front-loaded sentence with no wasted words. It efficiently conveys the source, scope, and key filters.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with 3 parameters (1 required), no output schema, and no annotations, the description provides adequate context: the source, version, and filterable aspects. However, it does not explain return format or pagination, making it minimally viable.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100%, so the baseline is 3. The description adds marginal value by mentioning 'sponsors, phases' which are not explicit parameters but hints at search capabilities. It does not elaborate on parameter syntax or format beyond the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Does the description clearly state what the tool does and how it differs from similar tools?

The description uses a specific verb ('Search') and resource ('480K+ clinical studies via ClinicalTrials.gov v2'). It lists key aspects (Status, sponsors, phases, results) that clearly distinguish it from siblings like search_pubmed which searches biomedical literature.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description does not provide any explicit guidance on when to use this tool versus alternatives (e.g., adverse_events, drug_labels). It lacks context about when not to use it or what complementary tools exist.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.